ArticleHuman gene therapy2012
Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses.
Article in Human gene therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Therapeutic melanoma vaccines: Platforms, neoantigen strategies, and emerging combination immunotherapies.Therapeutic advances in vaccines and immunotherapy · 2026Review
- Intradermal DNA vaccine delivery using vacuum-controlled, needle-free electroporation.Molecular therapy. Nucleic acids · 2023Article
- Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment.Nanomaterials (Basel, Switzerland) · 2022Review
- Safe and efficient novel approach for non-invasive gene electrotransfer to skin.Scientific reports · 2018Article
- Delineating the Cellular Mechanisms Associated with Skin Electroporation.Human gene therapy methods · 2018Article
- Multigenic DNA vaccine induces protective cross-reactive T cell responses against heterologous influenza virus in nonhuman primates.PloS one · 2017Article
- A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native Conformation.Frontiers in immunology · 2017Article
- Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus.The Journal of infectious diseases · 2016Article
- New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.Expert review of vaccines · 2016Review
- Article
- Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge.Mucosal immunology · 2016Article
- An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.Journal of virology · 2015Article
- Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells.Gene therapy · 2015Article
- DNA vaccination by intradermal electroporation induces long-lasting immune responses in rhesus macaques.Journal of medical primatology · 2014Article
- HIV DNA Vaccine: Stepwise Improvements Make a Difference.Vaccines · 2014Review
- Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques.Human vaccines & immunotherapeutics · 2013Article
- HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA represents an ideal vaccine platform for HIV and many infectious diseases because of its safety, stability, and ease of manufacture. However, the immunogenicity of DNA vaccines has traditionally been low compared with viral vectors, recombinant protein, and live attenuated vaccines. The immunogenicity of DNA vaccines has been significantly enhanced by delivery with in vivo electroporation. Further improvements now allow electroporation to be performed in the dermis, which could potentially improve patient tolerability and may further enhance immunogenicity. In this study we examined how the current of intradermal vaccination impacts antigen expression, inflammation, and the induction of both humoral and cellular immunity in guinea pigs and nonhuman primates. We observed that a lower (0.1 A) current reduced inflammation and improved antigen expression compared with a 0.2 A current. The improved antigen expression resulted in a trend toward higher cellular immune responses but no impact on HIV- and influenza-specific binding titers. This study highlights the need for optimization of electroporation conditions in vivo in order to balance enhanced plasmid transfection with a loss of expression due to tissue inflammation and necrosis. These results suggest that a lower, 0.1-A current may not only improve patient tolerability but also improve immunogenicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.